Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Arzneimittelforschung ; 57(6A): 385-91, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17691588

RESUMEN

The study was carried out as an open-label, but laboratory-blind, single-dose, single-centre, randomized, two-period crossover study. Twenty-two patients with iron deficiency anemia completed the study. The study consisted of two treatment phases of 36 h, separated by a washout period of between 6 and 14 days. The two treatments were given orally. The reference treatment was tetracycline (CAS 60-54-8) alone (2 x 250 mg capsules) and the test treatment was iron(III)-hydroxide polymaltose complex (IPC, Maltofer) together with tetracycline (2 x 250 mg capsules). IPC had no pharmacokinetic effect on the rate of absorption of tetracycline. With concomitant administration of tetracycline and IPC sufficiently high tetracycline concentrations, to ensure bacteriostasis, will be reached. An inhibitor effect of IPC to the tetracycline absorption, as it is known for ferrous salts, could not be observed.


Asunto(s)
Anemia Ferropénica/metabolismo , Antibacterianos/farmacocinética , Compuestos Férricos/efectos adversos , Tetraciclina/farmacocinética , Adulto , Algoritmos , Anemia Ferropénica/sangre , Anemia Ferropénica/tratamiento farmacológico , Área Bajo la Curva , Interacciones Farmacológicas , Femenino , Compuestos Férricos/farmacocinética , Compuestos Férricos/uso terapéutico , Semivida , Humanos , Absorción Intestinal/efectos de los fármacos , Masculino , Persona de Mediana Edad , Control de Calidad , Tamaño de la Muestra , Método Simple Ciego
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA